Oncology remains a cornerstone of Ipsen's business, delivering 4.1% growth and accounting for 69% of total 2025 sales. In December 2025, Ipsen expanded its immuno-oncology portfolio with the acquisition of ImCheck Therapeutics, developing next-generation immuno-oncology therapies including IPN60340 (ICT01), a first-in-class monoclonal antibody targeting BTN3A. The company leverages internal and external innovation alongside nearly 100 years of development experience across global hubs.
Cyborg Score Rationale
Ipsen demonstrates robust execution with 10.9% sales growth in 2025, strategic acquisitions strengthening its oncology pipeline, and recent FDA Breakthrough Therapy Designation for IPN60340. The company maintains solid margins (~35% core operating margin) and diversified revenue across three therapeutic areas, though regulatory and development risks remain inherent to pharma.
Top Insights
Rare Disease segment showed exceptional 102.5% growth in 2025, driven by products like Iqirvo and Bylvay
IPN60340 received FDA Breakthrough Therapy Designation in January 2026 for first-line unfit acute myeloid leukemia, accelerating development timeline
December 2025 ImCheck Therapeutics acquisition and Simcere Zaiming licensing agreement strengthen immuno-oncology capabilities
Operating in 40+ countries with presence in 100+ markets; nearly 100 years of development experience provides competitive moat
Named Competitors
Oncology Portfolio — Leading global oncology player with diverse immunotherapy and targeted therapy portfolio
Cell Therapy & Oncology — Major competitor in gene therapy, immunotherapy and targeted oncology
Immuno-Oncology — Established player in oncology and immunotherapy landscape
Biogen — Competitor in specialty pharma and rare disease segments
Recent Developments
(February 2026) FY 2025 strong results delivered: 10.9% sales growth CER with guidance upgrade for 2026
(January 2026) FDA grants IPN60340 Breakthrough Therapy Designation for first-line unfit acute myeloid leukemia
(December 2025) Acquisition of ImCheck Therapeutics announced for immuno-oncology expansion
(December 2025) Exclusive licensing agreement with Simcere Zaiming for SIM0613 (LRRC15-targeting ADC)
Open the full interactive Ipsen S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.